Cargando…
EML4-ALK与EGFR基因突变共存型非小细胞肺癌研究进展
Lung cancer is one of the most prevalence malignances, of which non-small cell lung cancer (NSCLC) account for 80%-85% of lung cancer. Molecular target therapy is one of the most popular and promising field of NSCLC treatment, and its hotspots includes EGFR (epidermal growth factor receptor), EML4-A...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2011
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999994/ https://www.ncbi.nlm.nih.gov/pubmed/22104224 http://dx.doi.org/10.3779/j.issn.1009-3419.2011.11.09 |